Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/58307
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAngela Paternaen_US
dc.contributor.authorRuttiros Khonkarnen_US
dc.contributor.authorSilva Mulhovoen_US
dc.contributor.authorAlexis Morenoen_US
dc.contributor.authorPatricia Madeira Girioen_US
dc.contributor.authorHélène Baubichon-Cortayen_US
dc.contributor.authorPierre Falsonen_US
dc.contributor.authorMaria José U. Ferreiraen_US
dc.date.accessioned2018-09-05T04:22:26Z-
dc.date.available2018-09-05T04:22:26Z-
dc.date.issued2018-01-15en_US
dc.identifier.issn14643391en_US
dc.identifier.issn09680896en_US
dc.identifier.other2-s2.0-85037656553en_US
dc.identifier.other10.1016/j.bmc.2017.11.052en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85037656553&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/58307-
dc.description.abstract© 2017 Elsevier Ltd Aiming at generating a library of bioactive indole alkaloid derivatives as multidrug resistance (MDR) reversers, two epimeric indole alkaloids (1 and 2) were submitted to chemical transformations, giving rise to twenty-four derivatives (5-28), bearing new aromatic or aliphatic azine moieties. The structure of the compounds was established by 1D and 2D NMR (COSY, HMBC, HMQC and NOESY) experiments. Two different strategies were employed for assessing their anti-MDR potential, namely through the evaluation of their activity as inhibitors of typical MDR ABC transporters overexpressed by cell transfection, such as ABCB1 (P-gp), ABCC1 (MRP1), and ABCG2 (BCRP), or by evaluating their ability as collateral sensitivity (CS) agents in cells overexpressing MRP1. A considerable MDR reversing activity was observed for compounds bearing the aromatic azine moiety. The strongest and most selective P-gp inhibition was found for the epimeric azines 5 and 6, bearing a para-methylbenzylidene moiety. Instead, compounds 17 and 18 that possess a di-substituted benzylidene portion with methoxy and hydroxyl groups, selectively inhibited MRP1 drug-efflux. None of these compounds inhibited BCRP. Compounds 5, 6 and 18 were further investigated in drug combination experiments, which corroborated their anti-MDR potential. Moreover, it was observed that compound 12, with an aromatic azine moiety, and compounds 23-26, sharing a new aliphatic substituent, displayed a CS activity, selectively killing MRP1-overexpressing cells. Among these last compounds, it could be established that addition of 19, 23 and 25 to MRP1-overexpressing cells led to glutathione depletion triggering cell death through apoptosis.en_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectChemistryen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleMonoterpene indole alkaloid azine derivatives as MDR reversal agentsen_US
dc.typeJournalen_US
article.title.sourcetitleBioorganic and Medicinal Chemistryen_US
article.volume26en_US
article.stream.affiliationsFaculdade de Farmacia, Universidade de Lisboaen_US
article.stream.affiliationsInstitut de Biologie et Chimie des Proteinesen_US
article.stream.affiliationsPedagogical Universityen_US
article.stream.affiliationsChiang Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.